Inhibition of TYRO3 can promote tumor cell ferroptosis, enhance the sensitivity of resistant tumors to anti-PD-1 therapy, and drive the development of a pro-tumor microenvironment by reducing the M1/M2 macrophage ratio (73). Here, TYRO3 is linked to neoplasm.